Viral-specific immunization in AIDS-related complex by photopheresis.
The potential for therapeutic intervention in 7 patients with AIDS-related complex (ARC) was evaluated through the use of photopheresis. The rationale for the study was based on: 1. the demonstration that psoralen and UVA could inactivate HIV/virus in vitro; 2. CD4 cells are the primary target population effected by HIV and photopheresis; and 3. reinfusion of inactivated virus and cell-associated virus might serve to engender an immune response. Preliminary results in 7 patients with ARC over 6 to 18 months revealed a virus-specific response with an elevation of HIV antibodies, while EBV and CMV titers remained unchanged. The immunologic results revealed an increase in the CD8 lymphocyte population, stable activation markers (B2 microglobulin neopterin), a decrease in p24 antigen titers and inability to culture HIV virus in 3 patients. All of these results were in the context of a stable or increasing CD4+ percent. Six patients did not reveal a generalized inhibition of other immune responses as demonstrated by recovery of DTH. In addition, the resolution of lymphadenopathy, night sweats, fever and weight loss, paralleled the immunologic response.
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
E
E
Bisaccia
C
C
Berger
F X
FX
DiSpaltro
S
S
Armus
C
C
Cahill
A
A
Klainer
D000386:AIDS-Related Complex / Q000276:immunology / Q000628:therapy*; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D006678:HIV / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D011701:PUVA Therapy; D013601:T-Lymphocytes / Q000276:immunology*; D001613:beta 2-Microglobulin / Q000032:analysis
D001613:beta 2-Microglobulin